Report Title:
Serine/Threonine Protein Kinase A Raf (Proto Oncogene A Raf or Proto Oncogene Pks or ARAF or EC 2.7.11.1) - Pipeline Review, H1 2018 Published On: January 2018
Category: Life Sciences
Pages: 28
Report Overview: Serine/Threonine Protein Kinase A Raf Proto Oncogene A Raf or Proto Oncogene Pks or ARAF or EC 2.7.11.1 Pipeline Review, H1 2018 Summary Serine/Threonine Protein Kinase A Raf Proto Oncogene A Raf or Proto Oncogene Pks or ARAF or EC 2.7.11.1 Serine/threonineprotein kinase ARaf is an enzyme that in humans is encoded by the ARAF gene. It is involved in the transduction of mitogenic signals from the cell membrane to the nucleus. It regulates the TOR signaling cascade. Serine/Threonine Protein Kinase A Raf Proto Oncogene A Raf or Proto Oncogene Pks or ARAF or EC 2.7.11.1 pipeline Target constitutes close to 5 molecules. Out of which approximately 5 molecules are developed by Companies. The molecules developed by companies in Phase II, Phase I and Preclinical stages are 1, 2 and 2 respectively. Report covers products from therapy areas Oncology which include indications Metastatic Melanoma, NonSmall Cell Lung Cancer, Solid Tumor and Colorectal Cancer. The latest report SerineThreonine Protein Kinase A Raf Pipeline Review, H1 2018, outlays comprehensive information on the Serine/Threonine Protein Kinase A Raf Proto Oncogene A Raf or Proto Oncogene Pks or ARAF or EC 2.7.11.1 targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action MoA, route of administration RoA and molecule type. It also reviews key players involved in Serine/Threonine Protein Kinase A Raf Proto Oncogene A Raf or Proto Oncogene Pks or ARAF or EC 2.7.11.1 targeted therapeutics development with respective active and dormant or discontinued projects. The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor
24marketreports | International +1 646 781 7170 | www.24marketreports.com
presentations and featured press releases from company/university sites and industryspecific third party sources. Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data. Scope The report provides a snapshot of the global therapeutic landscape for Serine/Threonine Protein Kinase A Raf Proto Oncogene A Raf or Proto Oncogene Pks or ARAF or EC 2.7.11.1 The report reviews Serine/Threonine Protein Kinase A Raf Proto Oncogene A Raf or Proto Oncogene Pks or ARAF or EC 2.7.11.1 targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industryspecific sources The report covers pipeline products based on various stages of development ranging from preregistration till discovery and undisclosed stages The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities The report reviews key players involved in Serine/Threonine Protein Kinase A Raf Proto Oncogene A Raf or Proto Oncogene Pks or ARAF or EC 2.7.11.1 targeted therapeutics and enlists all their major and minor projects The report assesses Serine/Threonine Protein Kinase A Raf Proto Oncogene A Raf or Proto Oncogene Pks or ARAF or EC 2.7.11.1 targeted therapeutics based on mechanism of action MoA, route of administration RoA and molecule type The report summarizes all the dormant and discontinued pipeline projects The report reviews latest news and deals related to Serine/Threonine Protein Kinase A Raf Proto Oncogene A Raf or Proto Oncogene Pks or ARAF or EC 2.7.11.1 targeted therapeutics Reasons to buy Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies Identify emerging players with potentially strong product portfolio and create effective counterstrategies to gain competitive advantage Identify and understand the targeted therapy areas and indications for Serine/Threonine Protein Kinase A Raf Proto Oncogene A Raf or Proto Oncogene Pks or ARAF or EC 2.7.11.1 Identify the use of drugs for target identification and drug repurposing Identify potential new clients or partners in the target demographic Develop strategic initiatives by understanding the focus areas of leading companies Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics Devise corrective measures for pipeline projects by understanding Serine/Threonine Protein Kinase A Raf Proto Oncogene A Raf or Proto Oncogene Pks or ARAF or EC 2.7.11.1 development landscape
24marketreports | International +1 646 781 7170 | www.24marketreports.com
Develop and design inlicensing and outlicensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Table of Contents: Table of Contents List of Tables List of Figures Introduction Global Markets Direct Report Coverage Serine/Threonine Protein Kinase A Raf Proto Oncogene A Raf or or EC 2.7.11.1 Overview Serine/Threonine Protein Kinase A Raf Proto Oncogene A Raf or or EC 2.7.11.1 Therapeutics Development Products under Development by Stage of Development Products under Development by Therapy Area Products under Development by Indication Products under Development by Companies Serine/Threonine Protein Kinase A Raf Proto Oncogene A Raf or or EC 2.7.11.1 Therapeutics Assessment Assessment by Mechanism of Action Assessment by Route of Administration Assessment by Molecule Type Serine/Threonine Protein Kinase A Raf Proto Oncogene A Raf or or EC 2.7.11.1 Companies Involved in Therapeutics Development Basilea Pharmaceutica Ltd Millennium Pharmaceuticals Inc Novartis AG Redx Pharma Plc Serine/Threonine Protein Kinase A Raf Proto Oncogene A Raf or or EC 2.7.11.1 Drug Profiles BAL3833 Drug Profile Product Description Mechanism Of Action R&D Progress LXH254 Drug Profile Product Description Mechanism Of Action R&D Progress REDX05358 Drug Profile Product Description Mechanism Of Action
Proto Oncogene Pks or ARAF Proto Oncogene Pks or ARAF
Proto Oncogene Pks or ARAF
Proto Oncogene Pks or ARAF
Proto Oncogene Pks or ARAF
24marketreports | International +1 646 781 7170 | www.24marketreports.com
R&D Progress Small Molecules to Inhibit PanRAF Kinase for Oncology Drug Profile Product Description Mechanism Of Action R&D Progress TAK580 Drug Profile Product Description Mechanism Of Action R&D Progress Serine/Threonine Protein Kinase A Raf Proto Oncogene A Raf or Proto Oncogene Pks or ARAF or EC 2.7.11.1 Discontinued Products Serine/Threonine Protein Kinase A Raf Proto Oncogene A Raf or Proto Oncogene Pks or ARAF or EC 2.7.11.1 Product Development Milestones Featured News & Press Releases Jun 09, 2016: Basilea reports presentation of data on clinical oncology program BAL3833 at ASCO meeting Apr 21, 2016: Basilea reports presentation of data on clinical oncology program BAL3833 at AACR meeting Sep 26, 2011: Sunesis Initiates Phase I Study Of MLN2480 In Advanced Solid Tumors Jul 13, 2009: Sunesis Pharmaceuticals Receives Milestone Payment From Biogen Idec Sep 07, 2004: Biogen Idec And Sunesis Form Collaboration To Discover And Develop Multiple Small Molecule Oncology Products Appendix Methodology Coverage Secondary Research Primary Research Expert Panel Validation Contact Us Disclaimer
Get More Information about the Report: Report URL: https://www.24marketreports.com/life-sciences/serinethreonine-protein-kinase-a-raf-proto-onco gene-a-raf-or-proto-oncogene-pks-or-araf-or-ec-27111pipeline-review-h1-2018-market-98 To get Report Sample: https://www.24marketreports.com/request-sample/serinethreonine-protein-kinase-a-raf-proto-o ncogene-a-raf-or-proto-oncogene-pks-or-araf-or-ec-27111pipeline-review-h1-2018-market-98
24marketreports | International +1 646 781 7170 | www.24marketreports.com